Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331674 | 0.86 | ALOX15 (0.33) | ALOX15ALOX12ESR1ESR2GABRA1 | |
| SCHEMBL25328994 | 0.86 | ALOX15 (0.33) | ALOX15ALOX12ESR1ESR2GABRA1 | |
| SCHEMBL25327492 | 0.79 | CYP3A4 (0.43) | ALOX15ALOX12CYP3A4 | |
| SCHEMBL25330005 | 0.78 | ALOX15 (0.37) | ALOX15ALOX12ESR1ESR2CYP3A4 | |
| SCHEMBL25329808 | 0.77 | ACHE (0.36) | ALOX15ALOX12ESR1CYP3A4ACHE | |
| SCHEMBL25329202 | 0.75 | GABRA1 (0.36) | ESR1ESR2GABRA1GABRB2HSPA5 | |
| SCHEMBL25329439 | 0.75 | ALDH1A1 (0.37) | ALOX15ALOX12GABRA1GABRB2 | |
| SCHEMBL25329288 | 0.75 | ALOX12 (0.43) | ALOX15ALOX12CYP3A4ACHE | |
| SCHEMBL25330034 | 0.74 | THRA (0.40) | ESR1ESR2 | |
| SCHEMBL25329941 | 0.74 | TP53 (0.31) | ALOX15ESR1ESR2CYP3A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | ALOX15 2186/4885ALOX12 1986/4885ESR1 3959/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | ALOX15 615/4885ALOX12 211/4885ESR1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.